SAVA - Cassava Sciences plunges 40% after simufilam researcher indicted on fraud charges
2024-06-28 13:52:13 ET
More on Cassava Sciences
- All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment
- Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials
- Cassava Sciences GAAP EPS of -$0.43 beats by $0.03
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences